Anagliptin

Anagliptin (INN; trade name Suiny) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It is approved for use in Japan.^[1] It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".^[2]

Anagliptin

Clinical data
Trade names	Suiny
Routes of administration	Oral
ATC code	none
Legal status
Legal status	Approved in Japan
Identifiers
IUPAC name N-[2-{{#parsoidfragment:1}}2-[(2S)-2-Cyanopyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
CAS Number	739366-20-2
ChemSpider	28492667
UNII	K726J96838
CompTox Dashboard (EPA)	DTXSID401045689
Chemical and physical data
Formula	C19H25N7O2
Molar mass	383.456 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N
InChI InChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1 Key:LDXYBEHACFJIEL-HNNXBMFYSA-N

Research

A systematic review and meta-analysis of anagliptin, published in 2024, found that it is effective in lowering blood glucose in people with type 2 diabetes and that it may lower cholesterol.^[3]